DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Late Chronic Phase Chronic Myelogenous Leukemia

Information source: M.D. Anderson Cancer Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Leukemia

Intervention: Gleevec (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: M.D. Anderson Cancer Center

Official(s) and/or principal investigator(s):
Jorge E Cortes, MD, Principal Investigator, Affiliation: The University Of MD Anderson Cancer Center

Summary

Objectives: Primary endpoints: To achieve low levels of PCR ratios of Bcr-Abl/Bcr (molecular CR) in a significant proportion of patients after 12 months of higher doses (800 mg daily) of Gleevec therapy To increase the proportion of patients achieving a complete cytogenetic response in patients with Ph-positive chronic phase CML using initial higher dose Gleevec therapy. Secondary endpoints: To evaluate the durations of PCR negativity, cytogenetic response, hematologic control, and survival. To analyze differences in response rates and in prognosis within different risk groups and patient characteristics

Clinical Details

Official title: Therapy of Late Chronic Phase Chronic Myelogenous Leukemia (CML) With High-Dose Gleevec (STI571)

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Cytogenetic CR Rate

Detailed description: Treatment: Imatinib mesylate is a new oral medication that blocks a protein that is responsible for CML Patients on this study will take 400 mg of imatinib twice daily (morning and evening). If you have side effects, the dose may be lowered. If you are taking less than 800 mg of imatinib, you can take your dose once per day or divided in two doses. Imatinib mesylate should be taken with a large glass of water. After completing 3 to 12 months of therapy, response to imatinib mesylate will be evaluated. Treatment may be continued for up to 20 years, or as long as it is judged best to control the leukemia. Update June 2010: Blood tests are recommended 2 times per year. Your doctor will discuss with you how often you should have blood tests. Bone marrow will be done if your doctor thinks it is necessary to check your disease. You must return to M. D. Anderson at least once every year. You may not need a bone marrow test every visit, but you will have blood drawn to measure the amount of disease you have. If the leukemia cannot be found for 2 years or longer on the blood test called PCR which is done to measure the amount of disease you have, your doctor may talk to you about stopping treatment with imatinib. If you and your doctor decide to stop your therapy, you will have a blood test for PCR done every 3 to 6 months. You do not need to return to M. D. Anderson to have this blood test done. You may have the blood taken by your local doctor and mailed to M. D. Anderson. If the leukemia is found again by the PCR blood test, your doctor may recommend that you restart treatment with imatinib. You may decide to stay on treatment with imatinib even if your PCR blood test does not show any sign of leukemia for 2 years or longer. This is an investigational study. The FDA has authorized the use of imatinib mesylate for patients with CML. It is the dose of imatinib mesylate being used that is investigational. A total of 50 patients will take part in this study. All will be enrolled at M. D. Anderson.

Eligibility

Minimum age: 15 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Patients age 15 years or older with a diagnosis of Ph-positive or Bcr-positive CML in chronic phase CML. They should be in at least one of the categories below: A.

Patients must have received interferon alpha and: - Failed to achieve or lost a

hematologic complete remission(after 3 months of therapy with interferon), or -

Failed to achieve or lost a major cytogenetic remission, or - Failed to achieve or

lost a complete molecular remission (competitive quantitative PCR <0. 05%), or - Were

intolerant to interferon B. Patients in late chronic phase (i. e., >/= 12 months from

diagnosis) who have not received treatment with interferon and: - Have high risk for

toxicity with IFN-A (e. g., age >/= 60 years), or - Refuse to use IFN-A

2. ECOG performance of 0-2. 3. Serum bilirubin less than 2mg%, serum creatinine less than 2mg%. Exclusion Criteria:

1. - NYHA Class 3-4 heart disease; Pregnant or lactating females

2. Women of pregnancy potential must practice contraception 3. Patients in accelerated phase (except clonal evolution) or blastic phase are

excluded. - Patients with clonal evolution as their only criterion for accelerated

phase are eligible. 4. Inclusion of women and minorities: As per NIH policy, women and members of minorities will be included in this protocol as they are referred in the CML population.

Locations and Contacts

The University Of MD Anderson Cancer Center, Houston, Texas 77030, United States
Additional Information

UT MD Anderson Cancer Center web site

Starting date: July 2001
Last updated: January 7, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017